Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Pacira BioSciences to post earnings of $0.64 per share for the quarter. Pacira BioSciences has set its FY 2024 guidance at EPS.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.71. The company had revenue of $181.24 million for the quarter, compared to analysts’ expectations of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Stock Performance

PCRX traded up $0.68 during trading on Wednesday, hitting $26.93. The stock had a trading volume of 71,023 shares, compared to its average volume of 485,121. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24. The firm has a market capitalization of $1.25 billion, a P/E ratio of 33.15 and a beta of 0.76. The company’s 50-day moving average price is $28.58 and its 200 day moving average price is $29.59. Pacira BioSciences has a twelve month low of $25.33 and a twelve month high of $47.01.

Insider Transactions at Pacira BioSciences

In other news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the transaction, the director now directly owns 22,127 shares in the company, valued at approximately $677,086.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the sale, the director now owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the sale, the director now directly owns 140,384 shares of the company’s stock, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Monday, March 4th. TheStreet raised shares of Pacira BioSciences from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Wedbush reaffirmed an “outperform” rating and set a $57.00 price target on shares of Pacira BioSciences in a research note on Thursday, February 8th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Pacira BioSciences in a research note on Thursday, March 7th. They set an “overweight” rating and a $45.00 price target on the stock. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $49.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.